HS-SPME-GC-MS approach for the analysis of volatile salivary metabolites and application in a case study for the indirect assessment of gut microbiota
In this work, a straightforward analytical approach based on headspace solid-phase microextraction coupled with gas chromatography-mass spectrometry was developed for the analysis of salivary volatile organic compounds without any prior derivatization step. With a sample volume of 500 μL, optimal conditions were achieved by allowing the sample to equilibrate for 10 min at 50 °C and then extracting the samples for 10 min at the same temperature, using a carboxen/polydimethylsiloxane fibre. The method allowed the simultaneous identification and quantification of 20 compounds in sample headspace, including short-chain fatty acids and their derivatives which are commonly analysed after analyte derivatization. The proof of applicability of the methodology was performed with a case study regarding the analysis of the dynamics of volatile metabolites in saliva of a single subject undergoing 5-day treatment with rifaximin antibiotic. Non-stimulated saliva samples were collected over 3 weeks from a nominally healthy volunteer before, during, and after antibiotic treatment. The variations of some metabolites, known to be produced by the microbiota and by bacteria that are susceptible to antibiotics, suggest that the study of the dynamics of salivary metabolites can be an excellent indirect method for analysing the gut microbiota. This approach is novel from an analytical standpoint, and it encourages further studies combining saliva metabolite profiles and gut microbiota dynamics.
KeywordsVolatile organic compounds Microbiota HS-SPME-GC-MS method Saliva
This work is dedicated to Dr Giovanni Battista Gervasi of Laboratori Baldacci, Pisa (Italy), who believed in the reliability of saliva analysis and in its potentialities in drug development.
Compliance with ethical standards
The study was conducted under approved Institutional Review protocol in accordance with the Declaration of Helsinki and in accordance with the ethical standards. All the volunteer donors provided written informed consent before study entry.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Panek M, Paljetak HC, Baresic A, Peric M, Matijasic M, Lojkic I, et al. Methodology challenges in studying human gut microbiota - effects of collection, storage, DNA extraction and next generation sequencing technologies. Sci Rep. 2018;8. https://doi.org/10.1038/s41598-018-23296-4.
- 2.Alonso A, Marsal S, JuliÃ A. Analytical methods in untargeted metabolomics: state of the art in 2015. Front Bioeng Biotechnol. 2015. https://doi.org/10.3389/fbioe.2015.00023.
- 7.Kamal F, Kumar S, Singanayagam A, Edwards M, Romano A, Veslkov K, et al. Volatile organic compound (VOC) analysis to differentiate between bacterial and viral respiratory infections in COPD. Eur Respir J. 2018;52:PA5301. https://doi.org/10.1183/13993003.congress-2018.PA5301.CrossRefGoogle Scholar
- 10.Michalke B, Rossbach B, Göen T, Schäferhenrich A, Scherer G, Hartwig A. Saliva as a matrix for human biomonitoring in occupational and environmental medicine [Biomonitoring Methods, 2015]. MAK-Collection Occup Heal Saf. 2016. https://doi.org/10.1002/3527600418.bisalivae2115.
- 24.Kageyama G, Saegusa J, Tanaka S, Takahashi S, Nishida M, Tsuda K, et al. Salivary metabolomics of primary Sjogren’s syndrome. Ann Rheum Dis. 2014;73:524–5. https://doi.org/10.1136/annrheumdis-2014-eular.1201.CrossRefGoogle Scholar
- 25.Hansen TH, Kern T, Bak EG, Kashani A, Allin KH, Nielsen T, et al. Impact of a vegan diet on the human salivary microbiota. Sci Rep. 2018;8. https://doi.org/10.1038/s41598-018-24207-3.
- 27.Wang J, Schipper HM, Velly AM, Mohit S, Gornitsky M. Salivary biomarkers of oxidative stress: a critical review. Free Radic Biol Med. 2015;85:95–104. https://doi.org/10.1016/j.freeradbiomed.2015.04.005.CrossRefPubMedGoogle Scholar
- 28.Abe K, Takahashi A, Fujita M, Hayashi M, Okai K, Ohira H. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. Hepatology. 2017;66:189A–90A.Google Scholar
- 31.Iwasawa K, Suda W, Tsunoda T, Oikawa-Kawamoto M, Umetsu S, Takayasu L, et al. Dysbiosis of the salivary microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a biomarker. Sci Rep. 2018;8. https://doi.org/10.1038/s41598-018-23870-w.
- 40.Soini HA, Klouckova I, Wiesler D, Oberzaucher E, Grammer K, Dixon SJ, et al. Analysis of volatile organic compounds in human saliva by a static sorptive extraction method and gas chromatography-mass spectrometry. J Chem Ecol. 2010;36:1035–42. https://doi.org/10.1007/s10886-010-9846-7.CrossRefPubMedGoogle Scholar
- 41.Brown SK, Sim MR, Abramson MJ, Gray CN. Concentrations of volatile organic compounds in indoor air – a review. Indoor Air. 1994;4:123–34. https://doi.org/10.1111/j.1600-0668.1994.t01-2-00007.x.CrossRefGoogle Scholar
- 45.Dolch ME, Hornuss C, Klocke C, Praun S, Villinger J, Denzer W, et al. Volatile organic compound analysis by ion molecule reaction mass spectrometry for Gram-positive bacteria differentiation. Eur J Clin Microbiol Infect Dis. 2012;31:3007–13. https://doi.org/10.1007/s10096-012-1654-2.CrossRefPubMedGoogle Scholar
- 47.Mal M. Noninvasive metabolic profiling for painless diagnosis of human diseases and disorders. Futur Sci OA. 2016;2. https://doi.org/10.4155/fsoa-2015-0014.
- 56.Madsen BS, Trebicka J, Thiele M, Israelsen M, Arumugan M, Havelund T, et al. Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial. Trials. 2018:19. https://doi.org/10.1186/s13063-018-2523-9.
- 59.Cash BD, Pimentel M, Rao SSC, Weinstock L, Chang L, Heimanson Z, et al. Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Ther Adv Gastroenterol. 2017;10:689–99. https://doi.org/10.1177/1756283x17726087.CrossRefGoogle Scholar
- 70.Del Chierico F, Nobili V, Vernocchi P, Russo A, Stefanis C, Gnani D, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65:451–64. https://doi.org/10.1002/hep.28572.CrossRefPubMedGoogle Scholar